The drop in Palisade Bio's stock price is likely due to the dilution effect of the new share issuance. The company's decision to raise funds through a direct offering indicates a need for cash, which could be perceived negatively by investors. However, the funds raised will be used for working capital and general corporate purposes, which could potentially improve the company's financial stability in the long run.